LeMaitre Vascular (NASDAQ:LMAT) Stock Passes Above 200-Day Moving Average – What’s Next?

LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $89.71 and traded as high as $108.68. LeMaitre Vascular shares last traded at $107.86, with a volume of 253,850 shares trading hands.

Wall Street Analyst Weigh In

LMAT has been the subject of several recent analyst reports. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, March 10th. Roth Mkm reiterated a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Finally, Barrington Research boosted their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $105.80.

LeMaitre Vascular Trading Up 1.5%

The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. The company has a 50 day simple moving average of $95.05 and a two-hundred day simple moving average of $89.71. The firm has a market cap of $2.46 billion, a PE ratio of 42.97, a P/E/G ratio of 3.06 and a beta of 0.66.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm had revenue of $64.45 million during the quarter, compared to analysts’ expectations of $62.98 million. During the same period last year, the business posted $0.49 earnings per share. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s payout ratio is 39.84%.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director David B. Roberts sold 8,464 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the sale, the director directly owned 17,979 shares of the company’s stock, valued at $1,920,157.20. This represents a 32.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 55,930 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the completion of the sale, the chief executive officer owned 1,476,500 shares in the company, valued at $159,181,465. The trade was a 3.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 215,438 shares of company stock worth $23,062,911. Company insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of LeMaitre Vascular by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after buying an additional 21,946 shares during the period. First Trust Advisors LP grew its holdings in LeMaitre Vascular by 13.4% during the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after acquiring an additional 111,193 shares during the period. State Street Corp grew its holdings in LeMaitre Vascular by 0.8% during the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after acquiring an additional 6,130 shares during the period. Congress Asset Management Co. raised its position in LeMaitre Vascular by 5.8% during the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after acquiring an additional 40,065 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in LeMaitre Vascular by 20.1% during the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after acquiring an additional 105,921 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.